LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
Daiichi Sankyo to expand its collaborative drug discovery program to Germany, Switzerland, and Austria

Daiichi Sankyo Company, Limited will expand its Take a New challenge for Drug diScovery (TaNeDS) Global Program, a collaborative drug discovery program with universities and research institutions based in Japan, to Germany, Switzerland and Austria. As part of the program, Daiichi Sankyo is seeking to work with innovative partners for research that could result in novel drug discovery candidates and novel new drugs.

The TaNeDS program is open to researchers of any nationality employed by universities, research institutes and start-up companies in Germany, Switzerland and Austria who can conduct research in those countries with projects that align with Daiichi Sankyo's research areas of interest, which include novel biologic agents (antibody drugs, etc.) for treatment of cancer, small-molecule cancer therapeutics, novel drug treatments for diabetes and complications of diabetes, novel mechanisms for genetic disorders, novel target molecules and delivery systems for nucleic acid treatments, and technology for protein x-ray crystallography.

Daiichi Sankyo and U3 Pharma GmbH (headquarters, Munich, Germany; hereafter, U3 Pharma), a wholly owned subsidiary of Daiichi Sankyo, will select institutions that match their research needs and demonstrate originality, potential and promise as drug discovery candidates.

The TaNeDS collaborative drug discovery project was launched in Japan in 2011 to help discover new lines of research through open innovation. Many researchers in Japan have applied to the program and research on selected themes is currently being conducted.

Click here for the complete issue.

news Runners' High, Happy Feet — If you're Happy, and you know it 'Clap' your Feet
news Snapshot of Stem Cell Expression using Single-cell RNA Sequencing
news A Heroic Voyage — Sydney Brenner's Life in Science
news VeloX, A Minimally Invasive Prosthetic Heart Valve for treating Mitral Regurgitation
news Anti-CD25 monoclonal antibody (90Y-daclizumab) a favorable target towards systemic radio-immunotherapy in Hodgkin's Lymphoma

Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy